Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):157-67Oncolytic virus therapy–foreword
/in International Publications, Newcastle Disease Virus /von 2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):123-5Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions
/in International Publications, Newcastle Disease Virus /von 2007-01-15 / Cancer Res. 2007 Jan;67(2):429-32p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2007-01-10 / J. Virol. 2007 Mar;81(6):2817-30Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid
/in Brain Tumors in Children, Glioblastoma, International Publications, Newcastle Disease Virus /von 2006-10-01 / APMIS 2006 Oct;114(10):731-43Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death
/in International Publications, Newcastle Disease Virus /von 2006-08-01 / J. Virol. 2006 Aug;80(15):7522-34Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence
/in International Publications, Newcastle Disease Virus /von 2006-07-15 / Int. J. Cancer 2006 Jul;119(2):328-38A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization
/in International Publications, Newcastle Disease Virus /von 2006-04-15 / Clin. Cancer Res. 2006 Apr;12(8):2555-62Combined action of virus injection and local tumor irradiation on tumor growth in mice
/in International Publications, Newcastle Disease Virus /von 2006-03-01 / Coll Antropol 2006 Mar;30(1):185-9
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- From Localized Mild Hyperthermia to Improved Tumor Oxygenation: Physiological Mechanisms Critically Involved in Oncologic Thermo-Radio-Immunotherapy
- Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
- Immunotherapy in breast cancer: an overview of current strategies and perspectives